HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Fischer, R. Articles by Huber, R.M. Search for Related Content PubMed PubMed Citation Articles by Fischer, R. Articles by Huber, R.M.

Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude

¹ Dept of Medicine, Division of Pneumology, Medizinische Klinik - Innenstadt, University of Munich, Munich, and ² Klinik Bad Reichenhall, Bad Reichenhall, Germany.

CORRESPONDENCE: R. Fischer, Pneumology, Medizinische Klinik - Innenstadt, LMU München, Ziemssenstrasse 1, D-80336, München, Germany. Fax: 49 8951604905. E-mail: rainald.fischer@med.uni-muenchen.de

Keywords: acetazolamide, high altitude, sleep-disordered breathing, theophylline

Received: December 6, 2002
Accepted June 27, 2003

This study was supported by Deutsche Akademie für Flug- und Reisemedizin, Frankfurt and Radiometer Inc., Munich, Germany.

A randomised, double-blind, placebo-controlled study was conducted to evaluate the effects of theophylline and acetazolamide in the treatment of sleep-disordered breathing (SDB) after fast ascent to high altitude (3,454 m).

The study was conducted at a high-altitude research laboratory and included 30 healthy male volunteers. Study medication was either oral slow release theophylline (2x250 mg·day^–1), oral acetazolamide (2x250 mg·day^–1) or a matched placebo tablet. Polysomnographic measurements were performed during two consecutive nights, and acute mountain sickness, pulse rate, oxyhaemoglobin saturation and arterial blood gases were assessed three times a day.

Without active medication, the apnoea/hypopnoea index (AHI) was highly pathological (median 16.2·h^–1, range 2–92). Both theophylline and acetazolamide normalised SDB (median AHI 2.5·h^–1, range 0–11; 4.2·h^–1, range 0–19, respectively) and reduced oxyhaemoglobin desaturations during sleep (median desaturation index placebo 41.5·h^–1, range 6–114; acetazolamide 6.5·h^–1, range 3–28; theophylline 8.5·h^–1, range 3–32). Compared with the high amount of central apnoeas or hypopnoeas, the number of obstructive events during sleep was very low in all groups (<4·h^–1). In contrast to theophylline, acetazolamide significantly improved basal oxyhaemoglobin saturation during sleep (86.2±1.7% versus 81.0±3.0%).

The authors conclude that both oral slow release theophylline and acetazolamide are effective to normalise high-altitude sleep-disordered breathing.

This article has been cited by other articles:

				S. Javaheri Treatment of obstructive and central sleep apnoea in heart failure: practical options Eur. Respir. Rev., December 1, 2007; 16(106): 183 - 188. [Abstract] [Full Text] [PDF]

				A. M. Luks and E. R. Swenson Travel to high altitude with pre-existing lung disease Eur. Respir. J., April 1, 2007; 29(4): 770 - 792. [Abstract] [Full Text] [PDF]